Josh Schimmer
Stock Analyst at Cantor Fitzgerald
(4.41)
# 330
Out of 5,146 analysts
147
Total ratings
54.55%
Success rate
17.97%
Average return
Main Sectors:
Stocks Rated by Josh Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $95 → $130 | $107.50 | +20.93% | 7 | Dec 8, 2025 | |
| JANX Janux Therapeutics | Maintains: Overweight | $200 → $150 | $13.81 | +986.17% | 7 | Dec 2, 2025 | |
| DMAC DiaMedica Therapeutics | Initiates: Overweight | $25 | $8.65 | +189.02% | 1 | Nov 14, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Overweight | $120 → $200 | $124.43 | +60.73% | 1 | Nov 6, 2025 | |
| CABA Cabaletta Bio | Maintains: Overweight | $15 → $30 | $3.51 | +754.70% | 3 | Oct 31, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $100 → $110 | $68.85 | +59.77% | 13 | Oct 30, 2025 | |
| NUVL Nuvalent | Initiates: Overweight | $135 | $106.70 | +26.53% | 1 | Oct 15, 2025 | |
| IVVD Invivyd | Initiates: Overweight | $10 | $1.76 | +468.18% | 1 | Oct 6, 2025 | |
| RNA Avidity Biosciences | Maintains: Outperform | $70 → $65 | $72.75 | -10.65% | 6 | Sep 22, 2025 | |
| CGON CG Oncology | Reiterates: Overweight | $75 | $58.97 | +27.18% | 5 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $22.12 | - | 3 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $32.25 | -22.48% | 4 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $8 | $4.36 | +83.70% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $11.62 | +115.15% | 1 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 → $6 | $7.98 | -24.81% | 2 | Jun 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $260 → $280 | $234.47 | +19.42% | 4 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $12.61 | +296.51% | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $20 | $4.97 | +302.41% | 2 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $269.01 | -20.08% | 5 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $5 | $2.22 | +125.23% | 4 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.01 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $9.40 | +219.15% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $10.28 | - | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.31 | - | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $44.78 | +100.98% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.39 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $154.21 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $64.18 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.45 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.12 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $113.82 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 | $5.95 | +1,918.50% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $44.13 | +47.29% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $43 → $5 | $13.98 | -64.22% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $11 | $13.92 | -20.98% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $140 → $130 | $131.56 | -1.19% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $760 | $785.04 | -3.19% | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $24.35 | -38.39% | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $14.09 | +290.35% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $1.30 | +2,207.69% | 1 | Dec 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $1.18 | - | 4 | Dec 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $8.68 | - | 3 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $222 → $250 | $439.31 | -43.09% | 4 | Nov 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $99.95 | - | 2 | Jun 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $83.84 | - | 2 | May 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $3.97 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $23.83 | -7.68% | 1 | Nov 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $19.43 | - | 2 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $61.62 | - | 1 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $231.76 | -59.01% | 1 | Aug 17, 2017 |
Mirum Pharmaceuticals
Dec 8, 2025
Maintains: Overweight
Price Target: $95 → $130
Current: $107.50
Upside: +20.93%
Janux Therapeutics
Dec 2, 2025
Maintains: Overweight
Price Target: $200 → $150
Current: $13.81
Upside: +986.17%
DiaMedica Therapeutics
Nov 14, 2025
Initiates: Overweight
Price Target: $25
Current: $8.65
Upside: +189.02%
Palvella Therapeutics
Nov 6, 2025
Maintains: Overweight
Price Target: $120 → $200
Current: $124.43
Upside: +60.73%
Cabaletta Bio
Oct 31, 2025
Maintains: Overweight
Price Target: $15 → $30
Current: $3.51
Upside: +754.70%
BridgeBio Pharma
Oct 30, 2025
Maintains: Overweight
Price Target: $100 → $110
Current: $68.85
Upside: +59.77%
Nuvalent
Oct 15, 2025
Initiates: Overweight
Price Target: $135
Current: $106.70
Upside: +26.53%
Invivyd
Oct 6, 2025
Initiates: Overweight
Price Target: $10
Current: $1.76
Upside: +468.18%
Avidity Biosciences
Sep 22, 2025
Maintains: Outperform
Price Target: $70 → $65
Current: $72.75
Upside: -10.65%
CG Oncology
Sep 8, 2025
Reiterates: Overweight
Price Target: $75
Current: $58.97
Upside: +27.18%
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $22.12
Upside: -
Sep 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $32.25
Upside: -22.48%
Aug 8, 2025
Maintains: Overweight
Price Target: $10 → $8
Current: $4.36
Upside: +83.70%
Jul 1, 2025
Initiates: Overweight
Price Target: $25
Current: $11.62
Upside: +115.15%
Jun 23, 2025
Downgrades: In-Line
Price Target: $11 → $6
Current: $7.98
Upside: -24.81%
May 2, 2025
Maintains: Outperform
Price Target: $260 → $280
Current: $234.47
Upside: +19.42%
Apr 1, 2025
Reiterates: Overweight
Price Target: $50
Current: $12.61
Upside: +296.51%
Mar 25, 2025
Maintains: Overweight
Price Target: $23 → $20
Current: $4.97
Upside: +302.41%
Feb 20, 2025
Reiterates: Overweight
Price Target: $215
Current: $269.01
Upside: -20.08%
Dec 20, 2024
Downgrades: In-Line
Price Target: $5
Current: $2.22
Upside: +125.23%
Dec 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.01
Upside: -
Oct 8, 2024
Reiterates: Overweight
Price Target: $30
Current: $9.40
Upside: +219.15%
Sep 23, 2024
Downgrades: Neutral
Price Target: n/a
Current: $10.28
Upside: -
Sep 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.31
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $90
Current: $44.78
Upside: +100.98%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.39
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $154.21
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $64.18
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.45
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.12
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $113.82
Upside: -
Aug 26, 2024
Maintains: Outperform
Price Target: $120
Current: $5.95
Upside: +1,918.50%
Aug 9, 2024
Reiterates: Overweight
Price Target: $65
Current: $44.13
Upside: +47.29%
Nov 10, 2023
Downgrades: In-Line
Price Target: $43 → $5
Current: $13.98
Upside: -64.22%
Jun 6, 2023
Maintains: Outperform
Price Target: $20 → $11
Current: $13.92
Upside: -20.98%
Nov 14, 2022
Downgrades: In-Line
Price Target: $140 → $130
Current: $131.56
Upside: -1.19%
Oct 17, 2022
Downgrades: In-Line
Price Target: $760
Current: $785.04
Upside: -3.19%
Mar 15, 2022
Initiates: Outperform
Price Target: $15
Current: $24.35
Upside: -38.39%
Feb 2, 2021
Initiates: Outperform
Price Target: $55
Current: $14.09
Upside: +290.35%
Dec 29, 2020
Initiates: Outperform
Price Target: $30
Current: $1.30
Upside: +2,207.69%
Dec 9, 2019
Downgrades: In-Line
Price Target: n/a
Current: $1.18
Upside: -
Feb 25, 2019
Upgrades: Outperform
Price Target: n/a
Current: $8.68
Upside: -
Nov 16, 2018
Upgrades: Outperform
Price Target: $222 → $250
Current: $439.31
Upside: -43.09%
Jun 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $99.95
Upside: -
May 8, 2018
Downgrades: In-Line
Price Target: n/a
Current: $83.84
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $3.97
Upside: -
Nov 7, 2017
Initiates: Outperform
Price Target: $22
Current: $23.83
Upside: -7.68%
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $19.43
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $61.62
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: $95
Current: $231.76
Upside: -59.01%